We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Consort Medical Plc | LSE:CSRT | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,010.00 | 1,005.00 | 1,010.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCSRT
RNS Number : 4841M
Consort Medical PLC
28 July 2017
Consort Medical plc
28 July 2017
Posting of Annual Report and AGM Notice
Consort Medical plc announces that it has published its Annual Report and Accounts 2017 and Notice of 2017 Annual General Meeting. The Annual General Meeting will be held at 2.00 p.m on Wednesday 6 September 2017 at the Company's registered office, Suite B, Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire HP2 4TZ.
Copies of the following documents will shortly be available to view on the Company's website at www.consortmedical.com
-- Annual Report and Accounts 2017; and -- Notice of 2017 Annual General Meeting.
In accordance with Listing Rule 9.6.1, a copy of each of these documents has been uploaded to the National Storage Mechanism and will be available for viewing shortly at www.hemscott.com/nsm.do
Hard copies have also been sent to those shareholders who have elected to continue to receive paper communications.
The Preliminary Results for the year ended 30 April 2017 were announced on 15 June 2017.
The information contained in Appendix 1 (Principal Risks and Uncertainties) and Appendix 2 (Statement of Directors' Responsibilities), which is extracted from the Annual Report and Accounts, is also included in the announcement for the sole purpose of complying with Rule 6.3.5 of the Disclosure and Transparency Rules. Page numbers and cross-references in the extracted information refer to page numbers and cross-references in the Annual Report and Accounts.
ENQUIRIES:
John Ilett
Company Secretary
01442 867920
Appendix 1
Principal Risks & Uncertainties
The Group's performance and prospects may be affected by risks and uncertainties relating to our business and operating environment.
Our internal controls include risk management processes to identify key risks and, where possible, to manage those risks through systems and processes and by implementing specific mitigation strategies. The most significant risks identified through our progressive review of the risk register that could materially affect the Group's ability to achieve its financial and operating objectives are summarised in this section. Other risks are either unknown or deemed less material.
Risk Controls and Mitigating Actions Trend ------------------------------------- ---------------------------------------- --------- Reliance upon key customers/products: The Group has significant á Both Aesica and Bespak Intellectual Property with have a degree of reliance associated barriers to entry. on a relatively small Regulatory licencing reduces number of key customers/products customers' ability to transfer and the loss of one such business elsewhere so a loss customer/product could of business once approved lead to a significant on a customer programme is reduction in revenues. unusual. The Group maintains a close dialogue with all of its customers and seeks to enter into long term supply agreements where appropriate. The Group's strategy of diversification has opened up a broader range of products and customers, and is progressively diluting customer/product concentration. ------------------------------------- ---------------------------------------- --------- Major operational incident: Where possible, manufacturing à A major incident (e.g. is split into discrete buildings fire) at a manufacturing for separate operations providing site may result in the some level of isolation for closure of a site causing certain products. The Group disruption to key supply carries out critical plant chain and loss of assets, risk and remediation assessments revenues and profit. at each of its manufacturing sites. High-profile near-miss reporting is performed to raise awareness of potential risks. Business continuity plans are also in place at major sites. ------------------------------------- ---------------------------------------- --------- Growth risk: The Group's The Group has well-honed programme à growth strategy is achieved planning and management processes. through four key elements: These provide good visibility sustained organic revenue of resource requirements, growth, operating leverage, whether capital, space, equipment innovation and enhancing or people, and enable timely acquisitions/investments. fulfilment on multiple parallel Delivery of growth carries programmes. Programme management the risk of execution techniques are risk based due to allocation of and highlight risks and challenges resources and new areas for increased management focus. of expertise. ------------------------------------- ---------------------------------------- --------- Acquisition risk: Failure The Group uses a clear set à to successfully execute of criteria for making acquisition or attain strategic objectives decisions while also engaging from the Group's acquisitions a long standing set of advisors may adversely affect who provide advice throughout the Group's financial an acquisition process. Appropriate performance and position. due diligence is performed Despite due diligence, on all potential mergers and changes in circumstances acquisitions. All acquisition could mean that initial plans are reviewed and sanctioned expectations are not by the Board. Warranties and met in whole or in part. indemnities are also sought from the seller, which act to further reduce risk/exposure in certain areas. ------------------------------------- ---------------------------------------- --------- Legal risk: As an international The Group limits such risks à enterprise, the Group by means of review by the must comply with differing Legal department and, where laws in different jurisdictions. appropriate, by consulting This can result in a external specialists on national wide range of risks relating laws in the jurisdictions to contract, competition, concerned. There is a specific trademark, patent and anti-corruption and anti-bribery anti-bribery/corruption policy which all employees laws. Significant penalties, are required to comply with such as fines, the requirement and confirm their understanding. to comply with monitoring There is also a whistle blowing or self-reporting obligations policy in place and Bribery could materially adversely Act training is given to employees. affect our reputation, The Group is not aware of business or financial any risks from legal disputes performance. that could have a significant impact on its financial results or net assets. ------------------------------------- ---------------------------------------- --------- Political/Socio-economic The Group maintains open relationships à risk: The Group has operations with its customers and suppliers and customers in a number to ensure that we are up to of countries worldwide. date on any political/economic As a result it is subject conditions which may impact to political and socio-economic the business. The Group continually risks both globally and reviews any economic policy in individual countries. changes in both the UK and Political or economic Global markets and assesses instability may impact if there is any impact on the performance of our the business. business both operationally and financially. ------------------------------------- ---------------------------------------- --------- Development risk: Bespak The Group follows rigorous à is developing a range processes for the development of medical device products. of new products. Where possible, Aesica is providing pharmaceutical Bespak is developing its device product formulation development, technology as a platform for analytics and manufacturing multiple programmes to reduce services to pharmaceutical the exposure to any individual and biotech companies. trial. Aesica's development At any time, any of the services are on a fee per products may fail in project basis, with the large
clinical trials, be withdrawn majority of its revenues coming by the customer or may from manufacturing services. not become commercially successful once launched. ------------------------------------- ---------------------------------------- --------- Product quality failure: The Group has rigorous quality á The Group operates in management and assurance systems highly regulated markets and processes. Incoming raw with strict quality requirements. materials are analysed, production Any quality failure involving processes are controlled and the Group's products products are sampled for testing could lead to loss of prior to release. Any issues reputation, reduction are tracked and reported to in revenues, recall costs ensure that there is early or sanction by the regulators. communication with customers and regulatory bodies regarding any quality audits. ------------------------------------- ---------------------------------------- --------- Corporate Social Responsibility: The Group continually reviews à Our manufactured products and explores ways to ensure or other activities/decisions that its business operates of the Group may not in a responsible manner across be judged by the public, the key focus areas of: health governments or other and safety, environmental stakeholders as being management, our people, ethical socially responsible, business practices and how leading to reputational it interacts with and supports harm. local communities. The Corporate Responsibility Committee meet regularly and is responsible for reviewing the divisions' new programmes, assisting with resourcing and ensuring alignment to the overall Group strategy. ------------------------------------- ---------------------------------------- --------- Regulatory risk: The A strong regulatory compliance à operations of the Group regime is in place and the are subject to various Group has invested heavily stringent regulatory in ensuring compliance with requirements which carry health, safety and regulatory an element of compliance requirements. Regular reviews risk (e.g. environmental, and audits take place, not health & safety). only by regulatory bodies such as the FDA and MHRA but also by customers. Bespak is ISO 13485 accredited and operates SAP in all its main processes. Aesica's API facilities are inspected and approved by the FDA and all manufacturing sites are approved by the MHRA and comply with cGMP manufacturing standards and requirements. ------------------------------------- ---------------------------------------- --------- IT / Cyber Risk: The The Group adopts a risk based à Group is dependent on approach in responding to information technology: Cyber risks. The Group has its systems and infrastructure a dedicated IT department face certain risks, including who monitor and review access service disruptions and security, ensure that there the loss or theft of are regular back-ups of confidential sensitive or confidential information and data, perform information. Cyber crime disaster recovery procedures is increasing in sophistication, when required and manage investment consequences and incidence, in the Group's IT infrastructure. with risks including Continuous vigilance and training virus "infection", unauthorised are required to mitigate Cyber access (hacking), and security risks, as perpetrators email-based phishing are creative and dynamic on frauds. a wide spectrum of strategies. ------------------------------------- ---------------------------------------- --------- Human Resources: The Remuneration packages are à Group relies heavily reviewed on an annual basis on recruiting and retaining in order to ensure that the talented employees with Group can continue to attract, a diverse range of skills retain, incentivise and motivate and capabilities to meet its employees. The Group is its strategic objectives. also committed to working A lack of training, recruitment, on improving drivers of engagement, securing the long term such as increasing our employees' loyalty of sufficient understanding of our strategy, numbers of qualified performance and core values. personnel, demographic change and any resulting skills shortages could have a considerable impact on our success. ------------------------------------- ---------------------------------------- --------- Currency risk: As the Currency exposures are reviewed à Group is headquartered on a monthly basis. The Group in the UK, its functional has a currency hedging strategy currency is pounds sterling. in place to cover known transactional As the Group conducts currency exposures. The Group's a large part of its business European operations are naturally in Europe (Euro) and hedged whereas its UK operations also contracts in other hedge contracted non-GBP FX currencies including flows. The Group hedges its USD and Japanese Yen, Balance Sheet FX exposure exchange rate fluctuations by structuring its debt currency can have an impact on composition in line with the earnings. base currency of its assets. The City and analysts are aware of our currency exposures and the Group's results are reported in constant currency. ------------------------------------- ---------------------------------------- --------- Interest rate risk: The The terms of the facility à Group is subject to interest are reviewed by the Board rate risk on its revolving on a regular basis. In the credit facility which current low interest rate is currently based on environment, the Group has LIBOR/EURIBOR plus a decided not to hedge its floating margin. rate debt into fixed rate for the time being. However, the Group actively monitors interest rates and debt markets and will manage any floating rate interest rate exposure, as appropriate. ------------------------------------- ---------------------------------------- --------- Liquidity and leverage The Group has strong cash à risk: Whilst the Group flows, and good earnings visibility has comfortable borrowing ensures that its margins are facilities and strong sufficient to exceed normal cash flows, there is operating costs. The business a risk of unforeseen is cash-generative, and there short term working capital are well-embedded cash and fluctuations which it working capital management may not be able to meet, processes. Current borrowing or which may breach covenants levels and financial covenants on its borrowing facilities. can be supported comfortably by forecast profit and cash flows. Covenant tests are performed bi-annually to determine whether the covenant tests are being met. Committed facilities are in place until September 2019. ------------------------------------- ---------------------------------------- --------- Pension risk: The Group The Group has full open dialogue á operates a number of with the Pension Trustees defined benefit pension and works closely with them
schemes which are valued to ensure that the Defined based upon a number of Benefit Schemes are adequately actuarial assumptions. funded and that the assets Fluctuations as well are invested appropriately. as errors or misstatements The Bespak Scheme was closed in these assumptions to future accrual in March may result in the pension 2016 and has been closed to schemes being underfunded new members since 2002. The or valued incorrectly. total deficit on the Bespak pension scheme was GBP40.6m at 30 April 2017. Aesica has three defined benefit schemes in Germany and Italy, two of which are closed to new members. The total deficit on the Aesica pension schemes was GBP4.0m at 30 April 2017 (See Note 21). ------------------------------------- ---------------------------------------- --------- Distributable reserves: The Group monitors distributable á Following the Brexit reserves prior to key reporting vote and subsequent changes periods and in an amplified in UK monetary policy, update provided within the corporate bond yields Board dividend paper. The have fallen sharply, Group's tax advisors EY have leading to substantial also completed our strategy increases in the Bespak for repatriation of profits pension deficit. The in overseas subsidiaries. Group continues to monitor the impact of this on its ability to pay dividends in future periods. ------------------------------------- ---------------------------------------- --------- Impact of Brexit: The We will continue to monitor á vote to leave the EU any impact on the group by has resulted in some monitoring any decisions made uncertainty, including by the UK government, maintaining currency volatility and regular interaction with tax a significant weakening colleagues and providing legal of sterling. Whilst the updates to the Board and the weakening of sterling Executive Committee. has had a beneficial translation impact on the Group's sterling results, it continues to monitor the impact of Brexit on its principal risks and any direct or indirect resultant complexities this may bring. ------------------------------------- ---------------------------------------- ---------
Appendix 2
Statement of directors' responsibilities
IN RESPECT OF THE ANNUAL REPORT AND THE FINANCIAL STATEMENTS
The directors are responsible for preparing the Annual Report and the Group and parent company financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare Group and parent company financial statements for each financial year. Under that law they are required to prepare the Group financial statements in accordance with IFRSs as adopted by the EU and applicable law and have elected to prepare the parent company financial statements on the same basis.
Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent company and of their profit or loss for that period. In preparing each of the Group and parent company financial statements, the directors are required to:
-- select suitable accounting policies and then apply them consistently; -- make judgements and estimates that are reasonable and prudent; -- state whether they have been prepared in accordance with IFRSs as adopted by the EU; and
-- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group and the parent company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the parent company's transactions and disclose with reasonable accuracy at any time the financial position of the parent company and enable them to ensure that its financial statements comply with the Companies Act 2006. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Group and to prevent and detect fraud and other irregularities.
Under applicable law and regulations, the directors are also responsible for preparing a Strategic Report, Directors' Report, Directors' Remuneration Report and Corporate Governance Statement that complies with that law and those regulations.
The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
Responsibility statement of the directors in respect of the annual financial report
We confirm that to the best of our knowledge:
-- the financial statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the company and the undertakings included in the consolidation taken as a whole; and
-- the strategic report and directors' report includes a fair review of the development and performance of the business and the position of the issuer and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face.
We consider the annual report and accounts, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the Group's position and performance, business model and strategy.
For and on behalf of the Board
John Ilett
Company Secretary
14 June 2017
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSPGUCCMUPMGCR
(END) Dow Jones Newswires
July 28, 2017 10:48 ET (14:48 GMT)
1 Year Consort Medical Chart |
1 Month Consort Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions